The combination of two of the used methodological approaches, TLC-immunostaining for aCL and ELISA for anti-CL/Vim complex antibodies, was able to detect aPL/cofactors in about two-thirds of OSN-APS patients with a small additional gain when also performing ELISA for aPS/PT or aCL and aβ2GPI IgA. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.